| Literature DB >> 34111727 |
Dong-Su Kim1, Yun-Jin Jeong1, Arunkumar Shanmugasundaram1, Nomin-Erdene Oyunbaatar1, Jongsung Park2, Eung-Sam Kim3, Bong-Kee Lee1, Dong-Weon Lee4.
Abstract
Herein, we propose a novel biosensing platform involving an array of 64 hybrid cantilevers and integrated strain sensors to measure the real-time contractility of the drug-treated cardiomyocytes (CMs). The strain sensor is integrated on the polyimide (PI) cantilever. To improve the strain sensor reliability and construct the engineered cardiac tissue, the nanogroove-patterned polydimethylsiloxane (PDMS) encapsulation layer is bonded on the PI cantilever. The preliminary sensing characteristics demonstrate the superior structural integrity, robustness, enhanced sensitivity, and repeatability of the proposed devices. The long-term durability and biocompatibility of the PI/PDMS hybrid cantilever is verified by evaluating the cell viability and contractility. We also validate the proposed biosensing platform for cardiotoxicity measurement by applying it to two specific cardiovascular drugs: quinidine and verapamil. In response to quinidine and verapamil, the engineered CMs exhibited negative inotropic and chronotropic effects. The fabricated cantilever device successfully detected the quinidine-induced adverse effects in CMs such as early after depolarization (EADs) and Torsade de points (TdP) in real-time. The array of hybrid cantilevers with integrated strain sensors has the potential to satisfy the need for innovative analytic platforms owing to its high throughput and simplified data analysis.Entities:
Keywords: Cardiomyocytes; Drug screening platform; High throughput; Hybrid cantilever arrays; Long-term stability
Year: 2021 PMID: 34111727 DOI: 10.1016/j.bios.2021.113380
Source DB: PubMed Journal: Biosens Bioelectron ISSN: 0956-5663 Impact factor: 10.618